Transcript of the Earning call held on May 08, 2026
NIVABUPA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Niva Bupa reported strong FY26 results with GWP of INR 9,433 crores (27.4% growth) and PAT of INR 366 crores (up 80% YoY) on Ind AS basis. Retail health growth was 35% with market share reaching 10.4% in Q4. The combined ratio improved by 160 bps to 101.4% under IFRS, driven by expense ratio reduction to 33.7% from 39.2% through operating leverage and economies of scale. Management guided that the combined ratio should reach 99% by FY29, translating to mid-to-high teens ROE, with savings coming entirely from expense ratio while loss ratio may inch up 100-150 bps. The company sees 17-19% CAGR for retail health industry over 5 years and expects ticket size growth to continue benefiting from GST impact. Renewal book is performing at 97-98% combined ratio.
Strong profitability improvement with 80% PAT growth and double-digit ROE signals improving operational efficiency. Management's clear FY29 margin target of 99% combined ratio provides visibility on earnings trajectory for shareholders.